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A NEW PERIDOL DERIVATIVE IN THE TREATMENT OF
CHRONIC SCHIZOPHRENIA*
T. BUCHAN, M.A., M.B., CH.B., F.F.PSYCH. (S.A.), DT.M. & H., Ingulsheni MenIal Hospital, Bulawayo, Rhodesia
The elderly chronic schizophrenic patient presents a for-
midable problem to the mental hospital. This has been in-
vestigated in Britain,' and the problem at Ingutsheni Hos-
pital appears fundamentally similar. A survey of patients
in the hospital on 31 December 1967 showed that 282 of
595 male patients (47%) and 94 of 213 female patients
(44%) were classified as schizophrenic. Of these schizo-
phrenic patients, 194 males (69%) and 57 females (61 %)
had been in hospital for 2 years or longer.
The effectiveness of drug therapy (as compared with
ECT alone, or psychotherapy alone) has been firmly estab-
lished' but the choice of drug is by no means clear. There
have been trials with African patients, e.g. with thiorida-
zine; but remission was not obtained with cases of more
than 5 years' standing.
Encouraging results were obtained with a peridol de-
rivative in very chronic African schizophrenic patients
who had been in hospital more than 20 years" This drug,
FR 33 (Sandoz), seemed to merit further trial.
MATERIALS AND METHODS
Because of difficulties with continuity of staff, only female
patients are included. Twenty patients were selected ac-
cording to the following criteria:
1. A minimum period of 5 years continuously in
hospital.
2. An initial diagnosis of schizophrenia on admission.
3. The diagnosis was supported in retrospective review
using the generally acceptable criteria set out by
Willis and Bannister:
The blood WR was negative in every case, but the EEG
proved to be abnormal in 2 patients who were therefore
excluded, leaving a total of 18.
AIl these 18 patients had been treated with various drug
combinations, with or without ECT, and none had shown
any sustained improvement. Further, the drug had been
shown to have a very low toxicity, both in animal experi-
ments and previous unpublished trials. These factors were
considered sufficient to render the trial ethicaIly justifiable.
Preliminary information intimated that the effects of the
drug would not be manifest until some 2 months' treat-
ment had been completed and that the action of the drug
would be sustained for at least 2 months after it had been
withdrawn.
The patients were therefore divided at random into 2
groups, an initial treatment group (group A) and an initial
'Date received: 19 July 1968.
placebo group (group B). It was intended that group A
should have treatment for 2 months, then change to the
placebo for 2 months; group B was intended to begin with
2 months on the placebo, then change to treatment for 2
months. If both hypotheses were correct, group A hould
have shown improvement at the end of 2 months, sus-
tained at the end of 4 months, and group B should have
shown no improvement at the end of 2 months but im-
provement after 4 months.
Since all patients, with the possible exception of Nos.
1526 and 7574 for whom the early records were incom-
plete, had had several courses of treatment previously, a
double-blind trial was not considered necessary. A 'single-
blind' trial was considered adequate (i.e. psychiatric ratings
to be done blind but the patients to be aware that they
were receiving different tablets although not aware that
one was a placebo). It was intended that there hould be
an initial psychiatric rating, one at 2 months and one at
4 months.
The scale selected was designed for use during a brief
interview and to give an index of the degree of 'p ychotic-
ness'" For the purposes of this investigation the last cate-
gory 'Judgement and abstracting ability' was omitted as it
was considered that language difficulties would preclude
any accurate assessment. In addition to the psychiatric
rating scale, a ward behaviour scale was completed by the
nursing staff at weekly intervals. The scale u ed was that
designed for use at Mohlomi Hospital, Lesotho,' and is
particularly suitable for African patients.
The patients were randomly divided into two groups of
9. With certain exceptions discussed below, the composi-
tion of the groups was not revealed to the investigators
until after the completion of the trial.
Conduct of the Trial
The trial commenced in December 1965. During this
month all patients were assessed on the psychiatric rating
scale by two investigators working separately. Compari-
son of results revealed that the inter-rater reliability was
not very high. This was partly due to conceptual difficul-
ties, in particular that of rating the patient with poverty
of ideation since the scale did not contain a category cor-
responding with 'negative formal thought di order'.'
These difficulties were resolved and all patients were
then rated by both investigators working in conjunction.
On this occasion only were the re ults of the previous
rating available to the investigator; at all other rating
a fresh rating sheet wa used to eliminate the effect of
'runs'."
284 S.A. TYDSKRIF VIR GENEESKUNDE 8 Maart 1969
The first ward behaviour rating was completed on
1 January, and on 3 January group A commenced FR 33
10 mg. t.d.s. and group B tabs. Vit. B Co. 1 t.d.s. Vitamin
supplements may cause psychiatric improvement,'· but
this was not considered a significant factor.
Contrary to expectation the nursing staff reported con-
siderable behavioural changes in patients in the treatment
group towards the end of the first month of the trial. In
order to allow for this, the design of the trial was altered
so that patients changed from treatment to placebo and
vice versa at the end of 1 month. Unfortunately, owing to
the absence on leave of one of the investigators it was not
possible to obtain a psychiatric rating at this stage, but
ward behaviour ratings were continued at weekly intervals
throughout. No change was observed in the placebo group.
After this change at the end of 1 month, the original trial
design was followed. That is, medication was as follows:
Group A. FR 33 10 mg. t.d.s. for 1 month
Vit. B Co. tabs. 1 t.d.s. for 2 months
FR 33 10 mg. t.d.s. for 2 months
Group B. Vit. B Co. tabs. 1 t.d.s. for 1 month
FR 33 10 mg. t.d.s. for 2 months
Vit. B Co. tabs. 1 t.d.s. for 2 months
Psychiatric ratings were completed on all patients ini-
tially, and after 2, 3 and 4 months.
Ward behaviour ratings were completed on all·patients
at weekly intervals throughout.
This pattern is set out in Fig. 1.
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Fig. 1. Pattern of ward behaviour ratings.
RESULTS
Side·effects of FR 33
In a previous unpublished trial of FR 33 in South
Africa, 4 out of 29 patients showed pre-collapse symptoms
with fall in blood pressure, sweating, nausea and vomiting.
Although the dosage in the present trial was much lower
(30 mg. daily as opposed to 50 mg.), daily blood pressure
records were kept by the nursing staff for patients on this
drug.
In group A, 2 patients showed a fall in blood pressure
of sufficient magnitude to warrant reduction of dosage. In
both cases the drug was withheld for 48 hours until the
systolic pressure had recovered to 100 mm.Hg; treatment
was then recommenced with 10 mg. b.d. One patient sub-
sequently died, and in the second leg of the trial the
surviving patient showed a transient fall in pressure a few
days after starting treatment, but she recovered spon-
taneously without reduction of dosage.
A further patient in group A contracted a brief febrile
illness. Her FR 33 was omitted for 48 hours in case there
should be any interference with antibody formation, but
she rapidly recovered and was given the full dosage for the
remainder of the month.
The code was broken for these 3 patients.
Psychiatric Changes in Response to FR 33
The compilers of the Psychiatric Rating Scale consider-
ed that one of the most meaningful ways of using the scale
was to take the whole scale score as an index of 'psy-
choticness'. The scale was used in this way and the scores
given are raw whole scale scores; the various correcting
factors were not applied since these would not have
affected the scores significantly and would have implied
an unjustified degree of clinical accuracy.
Comparison of the first two scores for each patient sug-
gested that rate/rerate variation was not likely to have
been a significant factor.
Since symptoms were given both positive and negative
signs, improvement was indicated by regression towards
zero; that is, an increase in the numerical value of a score,
whether of positive or negative sign, indicated a deteriora-
tion.
The ward behaviour rating scale did not have numerical
values attached to the behavioural categories, and for this
reason it was difficult to arrive at a global assessment of
the degree of illness. However, the over-all impressions of
the ward-sister provided valuable information of this kind,
while the ward behaviour rating scale assessments illumi-
nated changes in particular symptom groups.
In general there was a surprisingly close correlation be-
tween all three methods of assessment. The psychiatric
rating scale scores are set out in Tables I and IT for
groups A and B, respectively.
TABLE I. PSYCHIATRIC RATING SCALE SCORES FOR GROUP A
Date 0/ rating Result 0/
Patient's treatment with
No. 16/12/65 28/12/65 3/3/66 4/4/66 2/6/66 FR33
12091 + 6 + 7 +9 +14 +5 Deteriorated
7116 +26 +23 +13 +17 +18 Improved
7574 +17 +17 Died 6/2/66
11416 + 8 + 8 - 6 -5 Died 31/5/66
7561 + 8 + 8 - 1 -5 -27 Deteriorated
9350 +7 + 7 0 +11 +4 Deteriorated
6426 +10 +10 + 2 +3 +11 Unchanged
9955 + 1 +3 + 4 +7 + 3 Unchanged
8412 + 3 +6 +63 +17 - 2 Deteriorated
TABLE IT. PSYCHIATRIC RATING SCALES FOR GROUP B
Date of rating Result of
Patient's treatment with
No. 16/12/65 28/12/65 3/3/66 4/4/66 2/6/66 FR33
4017 +4 -4 + 5 + 9 +18 Deteriorated
11099 +15 +15 +11 + 9 + 6 . Improved
13679 +15 +19 + 3 + 8 +29 Improvement
12029 + 1 - 2
then relapse
+18 +14 +6 Unchanged
9527 + 3 +9 +2 +2 +9 Unchanged
1526 + 5 +7 - 5 -14 -17 Deteriorated
1351 +36 +36 +24 +31 +22 Deteriorated
7497 +4 + 7 +8 +5 + 1 Unchanged
7342 + 9 + 9 -9 +23 Died 19/4/66
There were no essential differences between the two
groups, and the patients' responses to FR 33 may be
summarIzed as: improved 3, unchanged 5, and deteri-
orated 10 (3 died).
Patients who improved. The predominant symptom pat-
terns of the 3 patients who improved were, respectively:
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The third patient died from bronchopneumonia but th·ere
was evidence of myocardial damage.
co CLU 10
The a.ction of FR 33 eem to be highly complex. Patients
may improve, either by becoming 'activated or by reduc-
tion of symptoms such as thought di order, hallucination
and delusions. Patients may deteriorate, and again the
deterioration may be in the form of reduced activity and
withdrawal or in the reactivation of hallucination , de-
lusions and thought disorder or motor activity.
The reaction of the patient eems to depend to ome
extent on the initial type of chizophrenia.
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SUMMARY
A new peridol derivative was tried in the treatment of 18
selected chronic female African schizophrenic patients.
A single-blind, cross-over design was used; the trial extended
over 5 months. Psychiatric ratings, ward behaviour ratings and
subjective reports by ward-sisters were used to assess progre s;
all three showed general agreement.
The actions of the drug proved to be complex, but a notable
feature was the reactivation of motor activity and ymptoms of
thought disorder. To some extent the response to the drug
seemed to depend upon the clinical picture before the onset of
schizophrenic deterioration.
Only 3 patients were rated as improved, and the drug was
not considered suitable for general u e, but might be of value
in selected cases, possibly in conjunction with phenothiazine.
I wish to thank Dr M. H. Webster, Secretary for Health for
permission to publish this paper; Dr A. P. Baker Medical
Superintendent of Ingutsheni Hospital, for permission to carry
out the study; Dr S. W. O. Caseley for assistance with the
psychiatric rating of patients; Mr A. W. A. Down and Sandoz
Ltd, for the supply of FR 33 tablets; and Sisters Abbey and
Davies and the staff of Lozikeyi Ward, for the ward behaviour
ratings.
thought disorder with hallucinations, and disorientation;
withdrawal and blunting of affect; and delusions and
auditory hallucinations.
All 3 showed some improvement in the first month, but
the third patient subsequently showed reactivation of her
delusions and hallucinations in a more fulminating and
bizarre form.
Patients who deteriorated. Of the 10 patients who de-
teriorated, one had presented with disconnected thinking,
hallucinations and inappropriately elated affect on ad-
mission, subsequently lapsing into generally withdrawn
behaviour with occasional aggressive and destructive out-
bursts. The FR 33 seemed to reactivate her delusions and
hallucinations and make her extremely overactive and
aggressive.
Thought disorder, present on admission, was reactivated
by FR 33 in 3 other patients. This reactivation of symp-
toms was also noted in an unpublished South Mrican
trial.
Three other patients in this group presented rather dif-
ferent pictures. One showed an initial change to over-
activity but became withdrawn and indolent after 2
months' treatment. Another, who had been quiet, un-
occupied and unresponsive, became hallucinated and
grossly overactive (singing and dancing); her score actually
showed a marginal improvement. The third patient showed
reduction of motor activity, facial expression and amount
of involvement with the examiner despite symptoms of
thought disorder with delusions and voluble disconnected
speech on admission.
Three patients died and postmortem examinations were
made in each case. Although none of the deaths could be
directly attributed to the drug, and deaths are more com-
mon in the winter months, it is possible that the induced
overactivity was a contributory factor. One died from
pulmonary tuberculosis after a brief illness lasting 3 days.
Another died from congestive failure due to myocardial
atrophy, and it is interesting to note that one South Afri-
can worker recorded a sudden death due to 'cardiac
dilatation' after FR 33 300 mg. daily for several weeks.'
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